Melanie Nicol, PharmD, PhD

Assistant Professor, Department of Experimental and Clinical Pharmacology (ECP)

Melanie Nicol

Contact Info

mrnicol@umn.edu

Office Phone 612-301-9511

Fax 612-626-9985

Office Address:
MTRF 4-210

Mailing Address:
Experimental and Clinical Pharmacology
2001 6th St SE
MTRF 4-210
Minneapolis, MN 55455

Lab Address:
MTRF 4-421

North Carolina Collaborative Clinical Pharmacology NIH Postdoctoral Training Program, UNC-Duke, Chapel Hill, NC

PharmD, Ohio Northern University Raabe College of Pharmacy

PhD, Pharmaceutical Sciences, UNC Eshelman School of Pharmacy, Chapel Hill, NC

Summary

Expertise

HIV/AIDS
Clinical Pharmacology
Women's Health
Drug Metabolism and Transport

Awards & Recognition

Deborah E. Powell Center for Women's Health Research Scholar

Professional Associations

Society of Infectious Disease Pharmacists
American Society of Clinical Pharmacology and Therapeutics
American Association of Pharmaceutical Scientists
American College of Clinical Pharmacy

Research

Research Summary/Interests

Our research efforts are focused on identifying factors that influence the efficacy of antivirals in tissue compartments. There is a paucity of data on the role of drug transporters and metabolizing enzymes in mucosal and lymphatic tissue compartments and yet drug distribution to these tissues is critically important for HIV prophylaxis, suppression of viral shedding, and eradication of viral reservoirs. Recent efforts have been focused on understanding antiretroviral disposition and efficacy in the female genital with the ultimate goal of improving HIV prevention options for women.

Publications

1) Nicol MR, Emerson CW, Fedoriw Y, Nelson JA, Sykes DC, Geller EJ, Prince HA, Patterson KB, Cohen M, Kashuba ADM. Models for Predicting Effective HIV Chemoprevention in Women. J Acquir Immune Defic Syndr. 2015 Apr; 68(4):369-376.

2) Thompson CG, Sedykh A, Nicol MR, Muratov E, Fourches D, Tropsha A, Kashuba ADM. Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. AIDS Res Hum Retroviruses. 2014 Nov; 30 (11):1058-64.

3) Nicol MR, Fedoriw Y, Mathews M, Prince HMA, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba ADM. Expression of Six Drug Transporters in Vaginal, Cervical, and Colorectal Tissues: Implications for Drug Disposition in HIV Prevention. J Clin Pharmacol 2014 May; 54(5):574-83

4) Nicol MR, Adams JL, Kashuba ADM. HIV pre-exposure prophylaxis trials: the road to success. Clin Invest. 2013 March; 3(3): 295-308.

5) Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest AF, Kashuba ADM. Pharmacokinetic Modeling of Efavirenz, Atazanavir, Lamivudine, and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. Clin Pharmacokinet. 2012 Dec;51(12):809-22.

6) Nicol MR, Kashuba ADM. Pharmacologic Opportunities for HIV Prevention. Clin Pharmacol Ther. 2010 Nov;88(5):598-609.

Teaching

Teaching Areas

Antivirals; Pharmacotherapy of Infectious Disease

Courses

PHAR 6768: Infectious Disease